Ofatumumab

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 987 publications

From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.

From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.

Journal: Journal of medical economics

Published: June 24, 2026

Letter to the editor regarding "Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice".

Letter to the editor regarding "Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice".

Journal: Neurodegenerative disease management

Published: May 24, 2026

Ofatumumab and enteroviral encephalitis: a severe infectious complication as a class effect with anti-CD20 therapies.

Ofatumumab and enteroviral encephalitis: a severe infectious complication as a class effect with anti-CD20 therapies.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: May 12, 2026

Uncoupling Relapse Reduction and Disability Progression: Evidence From Tolebrutinib Studies.

Uncoupling Relapse Reduction and Disability Progression: Evidence From Tolebrutinib Studies.

Journal: Neurology. Clinical practice

Published: May 11, 2026

Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort.

Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort.

Journal: Drugs - real world outcomes

Published: May 07, 2026

Patient‑Reported Satisfaction in Relapsing-Remitting Multiple Sclerosis: Advantages of At‑Home Self‑Administered Subcutaneous Ofatumumab Versus Other High‑Efficacy Therapies.

Patient‑Reported Satisfaction in Relapsing-Remitting Multiple Sclerosis: Advantages of At‑Home Self‑Administered Subcutaneous Ofatumumab Versus Other High‑Efficacy Therapies.

Journal: Drugs - real world outcomes

Published: April 06, 2026

Considerations for infection risks identified in target safety review.

Considerations for infection risks identified in target safety review.

Journal: The Journal of toxicological sciences

Published: April 01, 2026

Developing anti-CD20 molecules and B cell depletion in multiple sclerosis

Developing anti-CD20 molecules and B cell depletion in multiple sclerosis

Journal: Ideggyogyaszati szemle

Published: March 28, 2026

The impact of age on efficacy and safety of disease modifying treatment-insights from the Austrian Multiple Sclerosis Treatment Registry.

The impact of age on efficacy and safety of disease modifying treatment-insights from the Austrian Multiple Sclerosis Treatment Registry.

Journal: Journal of neurology

Published: March 14, 2026

Case Report: B-cell-targeted therapy with ofatumumab achieves remission in refractory panuveitis and coexisting multiple sclerosis.

Case Report: B-cell-targeted therapy with ofatumumab achieves remission in refractory panuveitis and coexisting multiple sclerosis.

Journal: Frontiers in neurology

Published: March 04, 2026

Clinical heterogeneity and immunotherapy outcomes in anti-GAD65 antibody-associated autoimmune encephalitis: a retrospective study.

Clinical heterogeneity and immunotherapy outcomes in anti-GAD65 antibody-associated autoimmune encephalitis: a retrospective study.

Journal: Therapeutic advances in neurological disorders

Published: March 03, 2026

Twenty-Four-Month Real-World Outcomes of Ofatumumab in Relapsing-Remitting Multiple Sclerosis: A Multicenter Retrospective Cohort Study.

Twenty-Four-Month Real-World Outcomes of Ofatumumab in Relapsing-Remitting Multiple Sclerosis: A Multicenter Retrospective Cohort Study.

Journal: Journal of clinical medicine

Published: March 02, 2026

Showing 1-12 of 987

Last Updated: 06/30/2026